retatrutide mechanism of action triple agonist glp-1 gip glucagon Retatrutide—A Game Changer in Obesity Pharmacotherapy The Road towards Triple Agonists:
Description
Lower ESRD prevalence in the GLP-1RA arm could similarly contribute modest positive confounding
The region benefits from high healthcare expenditure and widespread awareness about obesity-related health risks
Clinical Evidence# Amycretin Phase 1b/2a (Obesity, Lancet)# 125 adults with overweight or obesity
Rest of Africa 19.4
